Pair Name | Tetrandrine, Cisplatin | ||
Phytochemical Name | Tetrandrine (PubChem CID: 73078 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Tetrandrine, Cisplatin | |||
Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Expression | CASP3 | hsa836 | |
Down-regulation | Expression | CDH1 | hsa999 | |
Down-regulation | Expression | CTNNB1 | hsa1499 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Expression | VEGFA | hsa7422 | |
Down-regulation | Expression | WNT5A | hsa7474 | |
Down-regulation | Expression | WNT5B | hsa81029 | |
In Vitro Model | OVCAR-3 | High grade ovarian serous adenocarcinoma | Homo sapiens (Human) | CVCL_0465 |
Result | Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo |
No. | Title | Href |
---|---|---|
1 | Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo. Cancer Lett. 2011 May 1;304(1):21-32. doi: 10.1016/j.canlet.2011.01.022. | Click |